Raising awareness for the replication crisis in clinical psychology by focusing on inconsistencies in psychotherapy research : how much can we rely on published findings from efficacy trials? by Hengartner, Michael Pascal
OPINION
published: 28 February 2018
doi: 10.3389/fpsyg.2018.00256
Frontiers in Psychology | www.frontiersin.org 1 February 2018 | Volume 9 | Article 256
Edited by:
Nuno Conceicao,
Universidade de Lisboa, Portugal
Reviewed by:
Xavier Bornas,
University of the Balearic Islands,
Spain
Greg Murray,
Swinburne University of Technology,
Australia
*Correspondence:
Michael P. Hengartner
michaelpascal.hengartner@zhaw.ch
Specialty section:
This article was submitted to
Clinical and Health Psychology,
a section of the journal
Frontiers in Psychology
Received: 25 April 2017
Accepted: 15 February 2018
Published: 28 February 2018
Citation:
Hengartner MP (2018) Raising
Awareness for the Replication Crisis in
Clinical Psychology by Focusing on
Inconsistencies in Psychotherapy
Research: How Much Can We Rely on
Published Findings from Efficacy
Trials? Front. Psychol. 9:256.
doi: 10.3389/fpsyg.2018.00256
Raising Awareness for the
Replication Crisis in Clinical
Psychology by Focusing on
Inconsistencies in Psychotherapy
Research: How Much Can We Rely
on Published Findings from Efficacy
Trials?
Michael P. Hengartner*
Department of Applied Psychology, Zurich University of Applied Sciences, Zurich, Switzerland
Keywords: replication, clinical psychology, psychotherapy research, publication bias, allegiance, efficacy,
effectiveness, methodology
The replication crisis addresses a fundamental problem in psychological research. Reported
associations are systematically inflated and many published results do not replicate, suggesting
that the scientific psychological literature is replete with false-positive findings (Pashler and
Harris, 2012; Yong, 2012; Aarts et al., 2015). Unfortunately, the replication crisis remained almost
unanswered in clinical psychology until very recently. Leichsenring et al. (2017) and Tackett et al.
(2017) are to be complimented on their comprehensive recommendations for clinical science
replicability, as these two contributions were the first to address this important topic with respect
to clinical psychology. Their arguments are persuasive and elaborate, but some controversial topics
not detailed by these authors need to be addressed in order to provide a critical appraisal of ourmost
heeded research findings. Therefore, in order to raise awareness for the replication crisis in clinical
psychology, I will outline some specific issues underscoring that inconsistent and systematically
biased research findings persistently compromise the yield of clinical research. For it I will elaborate
on the efficacy of psychotherapy, which arguably is the most cited research topic within clinical
psychology.
PUBLICATION AND REPORTING BIAS INFLATES EFFICACY
Concerning replicability in psychotherapy research, themain question to pose is: Howmuch canwe
rely on the published evidence? To start with it needs to be acknowledged that the average efficacy of
psychotherapy based on the scientific literature is systematically overestimated due to publication
bias (Cuijpers et al., 2010a; Driessen et al., 2015; Cristea et al., 2017a). In accordance with findings
from psychopharmacological research (e.g., Turner et al., 2008), studies with unfavorable treatment
outcome are less likely to be published in the scientific literature. For instance, Driessen et al. (2015)
found that 24% of all trials aimed at evaluating the efficacy of psychological treatments for major
depression funded by the National Institutes of Health were not published, which led to a 25%
reduction in the estimated efficacy of psychotherapy (g = 0.52 vs. g = 0.39 after consideration of
unpublished trials). Similarly, focusing exclusively on the efficacy of cognitive-behavioral therapy
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(CBT) for adult major depression, Cuijpers et al. (2010a) reported
a reduction of 37% in efficacy after adjustment for publication
bias (d = 0.67 vs. d = 0.42 after imputation of unpublished
trials). On the individual study-level, some researchers use
selective outcome reporting to illegitimately present findings in
an opportunistic way. Outcome reporting bias is very prevalent
in clinical science and indicates that authors omit or change
primary outcomes on basis of the results in order to avoid
undesired findings (Dwan et al., 2008). For instance, Kirkham
et al. (2010) showed that adjusting for outcome reporting bias
reduced the primary treatment effect by 20% ormore in 23% of all
meta-analyses of clinical trials reviewed. They further state that
19% of meta-analyses with an initially significant result became
non-significant after adjustment for reporting bias. To the best
of my knowledge, reporting bias was not systematically tested
in psychotherapy research yet, but given its high prevalence
in clinical science (Dwan et al., 2008) it is very likely that
controlling for reporting bias would reduce the average efficacy of
psychotherapy even further than sole correction for publication
bias. Obtaining unbiased efficacy estimates for psychotherapy
trials from the published literature is obviously a serious
issue.
INCONSISTENT META-ANALYSES
The replication crisis in the clinical sciences becomes also evident
when one scrutinizes the literature on the comparative efficacy
of different psychotherapies. The allegiance bias means that
outcome studies in psychotherapy research are biased toward
the main authors’ psychotherapeutic allegiance (Luborsky et al.,
1999). In this regard it is important to specifically mention
three recent meta-analyses that came to completely divergent
conclusions on the relative efficacy of CBT vs. psychodynamic
therapy. In their meta-analysis, Leichsenring and Rabung (2011),
both devoted to psychoanalysis, concluded that long-term
psychodynamic therapy is markedly superior to short-term
modalities such as CBT. Conversely, Smit et al. (2012), found
no evidence for the superiority of long-term psychoanalysis
related to their primary outcome of recovery as well as to
all of their secondary outcomes comprising target problems,
general psychiatric symptoms, personality pathology, social
functioning, overall effectiveness, and quality of life. Finally,
a meta-analysis conducted by Tolin (2010) concluded that
CBT was superior to (short-term) psychodynamic therapy for
depression and anxiety disorders. Obviously, and in accordance
with an alarming issue recently detailed by Ferguson and Heene
(2012), changes in the study selection criteria and the analysis
procedure allow for producing almost any desired meta-analytic
outcome. Unfortunately, the scientific literature is amassed with
such examples. Thus, what shall we tell our patients: is long-
term psychoanalysis empirically supported or would they fare
better (or at least as good) with a short-term therapy such as
CBT? However, that may be, clinicians and researcher should be
aware that the credibility of many meta-analyses is rather modest
(Pereira and Ioannidis, 2011).
SYSTEMATIC BIASES ARE PERVASIVE
Another perennial hot topic in clinical psychology is the
efficacy of pharmacological vs. psychological treatments. In
a meta-analysis of direct comparisons, Cuijpers et al. (2013)
as well as Huhn et al. (2014) found no significant differences
between treatment modalities for panic disorder, generalized
anxiety disorder and social phobia. Conversely, focusing on
pre-post effect sizes, Bandelow et al. (2015) estimated that
pharmacotherapy was largely superior to psychotherapy for
these major anxiety disorders (d = 2.02, 95%-CI = 1.90–
2.15, for medications vs. d = 1.22, 95%-CI = 1.14–1.30, for
psychotherapies, p < 0.001). According to the authors this
finding cannot be explained by heterogeneity, publication
bias or allegiance effects (Bandelow et al., 2015). So, again
a largely inconsistent finding impedes stringent clinical
recommendations. Shall we recommend psychotropic drugs
as first-line treatment for major anxiety disorders or is
psychotherapy equally efficient? And what are the reasons for
such striking discrepancies between aggregated study results?
Cristea et al. (2017b) provide a partial explanation. In their
recent meta-analysis they showed that trials who were funded
by the pharmaceutical industry report slightly better outcomes
for pharmacotherapy relative to psychotherapy. Indeed, research
sponsored by the pharmaceutical industry or conducted by
authors with industry-related financial conflicts of interest
is systematically biased toward the industry’s vested interests
(Bekelman et al., 2003; Lexchin et al., 2003; Lundh et al.,
2012). Apparently researchers can willingly produce results
that match their (or their sponsors) expectations through
questionable research practices (Simmons et al., 2011; Bakker
et al., 2012). But financial interests and allegiance are only part
of the story; reputation and promotion are equally powerful
motives (Nosek et al., 2012). Differences in the study design
are another explanation for inconsistencies between research
findings. Khan et al. (2012) as well as Hróbjartsson et al. (2013)
showed that unblinded trial assessors systematically overestimate
the efficacy of the experimental intervention, and compared to
pharmacotherapy trials, psychotherapy trials use significantly
less blinded outcome assessors (Huhn et al., 2014). Given that
participants in psychotherapy trials are not blinded, patients’
treatment expectations and beliefs (see Chen et al., 2011)
may further inflate the apparent efficacy of psychotherapeutic
interventions. Finally, most psychotherapy trials use waitlist
conditions as comparator. However, waitlist designs do not only
produce larger efficacy estimates than trials with placebo or
routine care comparator (Cuijpers et al., 2016), they may even
impede or postpone spontaneous remission (Furukawa et al.,
2014), which is referred to as a nocebo effect. The meta-analysis
by Furukawa et al. (2014) is particularly revealing, as it showed
that response rate in CBT for depression did not appreciably
differ from psychological placebo (OR= 1.7), but it did so weakly
from no-treatment conditions (OR = 2.4) and markedly from
waitlist conditions (OR = 6.3). Likewise, comparing the effect
of psychotherapy for major depression to pill placebo, Cuijpers
et al. (2014b) found a poor effect size of g = 0.25, which is much
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smaller than the large effect sizes commonly obtained relative to
waitlist conditions.
ON TRIAL QUALITY AND EFFECTIVENESS
Study quality is an important determinant of treatment efficacy in
clinical science, but unfortunately, most published psychotherapy
trials use poor methods such as small sample sizes, inadequate
concealment of allocation, no intent-to-treat analyses, and
unblinded outcome assessors (e.g., Newby et al., 2015; Cristea
et al., 2017a). That hypothesis was stringently tested by Cuijpers
et al. (2010b) with respect to psychotherapy for adult depression.
Their results indeed revealed that high-quality studies are a small
minority and that they yield remarkably lower mean effect size
estimates than studies of lower quality (d = 0.22 vs. d = 0.74,
p < 0.001). Using a continuous measure of study quality ranging
from 0 to 8 points in a meta-regression showed that each
additional point increase in study quality reduced the average
effect size by−0.07 points (95%-CI=−0.09 to−0.05, p< 0.001).
The impact of low-quality study bias was very recently replicated
by Cristea et al. (2017a) in a meta-analysis of the efficacy of
psychotherapy for borderline personality disorder, suggesting
that these findings are generalizable. Worthy of note, the
estimates outlined above refer almost exclusively to efficacy under
controlled laboratory conditions using selected, unrepresentative
patient samples. Just as in pharmacological research (see Naci
and Ioannidis, 2015), evidence of efficacy for psychological
interventions under optimal laboratory conditions often does
not replicate in real world clinical settings (Westen et al., 2004).
Due to selective samples and unrepresentative clinical settings,
effectiveness of many empirically-supported psychological
interventions is inadequately poor under naturalistic real-world
conditions (Weisz et al., 1995; Hansen et al., 2002; Westen et al.,
2004). Furthermore, some psychological interventions with
proven laboratory-based efficacy turned out largely ineffective
(Hallfors and Cho, 2007) or even harmful (Lilienfeld, 2007)
in real-world effectiveness trials. That is, efficacy estimates
are not only inflated due to scientific and methodological
biases, they also poorly translate into measurable public
health benefits. However, a crucial point to consider is: “What do
psychotherapy trials actually measure?” Following the primacy of
the biomedical model of mental disorder, clinical psychology has
largely adapted the methods from pharmacology trials (Deacon,
2013). That is, symptom rating scales have become the primary
outcome in most trials, but this is not necessarily the domain
where psychotherapy has its most significant impact. Perhaps
psychotherapy’s major asset, in contrast to pharmacological
treatments, is to improve social functioning (e.g., Fournier et al.,
2015). Replicating effectiveness within these domains is perhaps
even more challenging than replicating symptom-based efficacy.
SUMMARY AND CONCLUSIONS
As in other psychological specialties (see Bakker et al., 2012),
effect sizes published in the clinical psychological literature are
often heterogeneous and inflated due to various scientific biases
including allegiance bias (Luborsky et al., 1999), publication
bias (Driessen et al., 2015), unblinded outcome assessors (Khan
et al., 2012), sponsorship bias (Cristea et al., 2017b), or small
sample sizes (Cuijpers et al., 2010b). After adjustment for
systematic biases, efficacy estimates for various psychotherapy
modalities tend to be disappointingly small (Cuijpers et al.,
2010b; Cristea et al., 2017a). Some evidence suggests that
when efficacy is estimated based exclusively on unbiased high-
quality trials, effects of psychotherapy could fall below the
threshold for clinical relevance (Cuijpers et al., 2014a). Recently,
some psychotherapy researchers hence raised the controversial
point that effects of both psychotherapy and pharmacotherapy
for depression may entirely reflect a placebo effect (Cuijpers
and Cristea, 2015). Of further concern is the gap between
treatment efficacy in controlled laboratory trials and treatment
effectiveness in naturalistic real-world settings (Westen et al.,
2004; Hallfors and Cho, 2007). The literature reviewed in
this commentary was restricted to the efficacy of clinical
psychological interventions, as that topic is highly relevant for
clinical psychology. Nevertheless, conflicting and irreproducible
findings have been detected and discussed in various other
hot topics within clinical psychology, including the debatable
effect of menopause on the occurrence of depression (Rössler
et al., 2016; Hengartner, 2017), the putative consequences of
violent video games (Ferguson and Kilburn, 2010; Calvert et al.,
2017), or inconsistent associations between psychopathology
and stress physiology (Chida and Hamer, 2008; Rosmalen
and Oldehinkel, 2011). Even though the replication crisis was
mostly addressed within social psychology, I conclude that
it is no less pernicious and prevalent in clinical psychology.
Psychotherapy was a marvelous invention, but initial enthusiasm
regarding its efficacy has now been obfuscated due to scientific
biases that systematically inflate estimates. Being aware of
these issues may certainly improve our scientific and clinical
endeavors.
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